Aardvark Therapeutics, Inc.

US$1.17As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AARDHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (66.02%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM (89.06%)
Mkt cap US$25.61M
ROIC (43.39%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.12
(4.43%)
(64.39%)
Hold 6|4|11|7|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.02
0.02
7.39%
19.29%
19.56%
19.81%
Revenue$M
1.640
1.598
1.607
1.562
5.75%
2.23%
(0.09%)
(4.42%)
Peers (US$25.61M)
Cap (US$)
PE
25.74M
—
25.64M
—
Capital
TTM
5Y
10Y
Leveragex
1.195
0.632
0.547
EBIT/Intx
0.801
0.177
0.174
Own earn%
41.49
(24.79)
(6.46)
Sh yield%
28.20
48.64
48.35
Owners
Insiders/Inst%
13.70
81.31
Short interest%
5.97
SBC / revenue%
3.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
18–29
$1 testx
—
Incr. ROIC%
6